RT Journal Article
SR Electronic
T1 Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.21.20216689
DO 10.1101/2020.10.21.20216689
A1 Harris, Ross J
A1 Whitaker, Heather J
A1 Andrews, Nick J
A1 Aiano, Felicity
A1 Amin-Chowdhury, Zahin
A1 Flood, Jessica
A1 Borrow, Ray
A1 Linley, Ezra
A1 Ahmad, Shazaad
A1 Stapley, Lorraine
A1 Hallis, Bassam
A1 Amirthalingam, Gayatri
A1 Höschler, Katja
A1 Parker, Ben
A1 Horsley, Alex
A1 Brooks, Timothy J G
A1 Brown, Kevin E
A1 Ramsay, Mary E
A1 Ladhani, Shamez N
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2020.10.21.20216689.abstract
AB Background Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England.Methods Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression.Findings In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥2 assays. Most seroconversions occurred between March and April 2020. The assays showed >85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12-16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50-68%) Euroimmun, 41% (30-52%) RBD, 10% (8-14%) Roche (N) <2% Roche (S).Interpretation Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was internally funded by Public Health England. BP is supported by the NIHR Manchester Biomedical Research Centre. At no time did any other author or their institutions receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by PHE Research Support and Governance Office (R&D REGG Ref NR 0190)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSharing of individual-level data is not permitted under the study protocol, although provision of aggregated data for specific purposes will be considered on request.